KalVista sees a win in PhII for the rare genetic disorder HAE as it continues to chart a post-Merck course
Roughly a year after Merck walked away from a partnership with KalVista following a flop in diabetic macular edema, the biotech is back with data from another program it hopes can put it back on the map.
KalVista reported topline Phase II results for its lead candidate KVD900, an oral therapy meant to stem the effects of swelling attacks caused by the rare genetic disorder hereditary angioedema. In the 53-patient trial, the program hit statistical significance across all endpoints, reducing the need for individuals to use further treatment in subsequent attacks and alleviating symptoms more quickly than placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.